



(51) International Patent Classification:

C07K 16/24 (2006.01) A01K 67/027 (2006.01)
A61K 39/395 (2006.01) C07K 14/54 (2006.01)
A61K 39/00 (2006.01) C07K 14/715 (2006.01)

(21) International Application Number:

PCT/EP2016/056973

(22) International Filing Date:

30 March 2016 (30.03.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/140,913 31 March 2015 (31.03.2015) US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).(72) Inventors: **COHEN, Emma, S**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **LOWE, David, C**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **BUTLER, Robin**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **SCOTT, Ian, C**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **VOUSDEN, Katherine, A**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **STRAIN, Martin, D**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **CARMEN, Sara**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **ENGLAND, Elizabeth, H**; MedImmune Limited Granta Park,

Cambridge Cambridgeshire CB21 6GH (GB). **KEMP, Benjamin, P**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **REES, David, G**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **OVERED-SAYER, Catherine, L**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **MUSTELIN, Tomas, M**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **SLEEMAN, Matthew**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **HOUSLAY, Kirsty**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(74) Agent: **WINTER, Christopher**; MedImmune Limited Milstein Building, Cambridge Cambridgeshire Granta Park (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

[Continued on next page]

(54) Title: A NOVEL IL33 FORM, MUTATED FORMS OF IL33, ANTIBODIES, ASSAYS AND METHODS OF USING THE SAME

FIG. 1

% Specific Binding												
	1	2	3	4	5	6	7	8	9	10	11	12
A	108	108	98	98	102	100	101	104	101	107	96	98
B	109	102	96	81	91	100	97	98	104	101	102	102
C	100	105	96	99	106	106	97	97	107	107	102	100
D	105	107	109	107	104	106	100	105	102	98	100	0
E	107	101	108	91	110	108	112	105	104	107	99	0
F	108	105	104	96	100	106	101	107	98	105	99	0
G	98	106	105	102	105	105	100	104	96	97	105	132
H	102	104	114	108	104	110	102	100	107	100	107	132

Well B04 = IL330004

Total binding
Non-specific binding

(57) Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*